当前位置: 首页 >> 检索结果
1. Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT.
作者: Feng Gao.;Xu Tong.;Ming Wei.;Xiaoxi Yao.;Lei Li.;Yuesong Pan.;Baixue Jia.;Thanh N Nguyen.;Ming Yang.;Dapeng Sun.;Ganghua Feng.;Guangxiong Yuan.;Chenghua Xu.;Zhengzhou Yuan.;Yue Wan.;Jing Wang.;Ping Jing.;Xinguang Yang.;Zhilin Wu.;Wei Hu.;Yuanfei Jiang.;Chaobin Wang.;Changming Wen.;Jianjun Tang.;Xiang Luo.;Yingchun Wu.;Ruile Shen.;Tuanyuan Zheng.;Yaxuan Sun.;Mingze Chang.;Yan Liu.;Yang Haihua.;Di Li.;Bo Yin.;Weihua Jia.;Dongjun Wan.;Guodong Xu.;Zaiyu Guo.;Dianjing Sun.;Yang Wang.;Jixin Duan.;Liyu Wang.;Guoqing Wang.;Liping Wei.;Gaoting Ma.;Xiaochuan Huo.;Dapeng Mo.;Ning Ma.;Zeguang Ren.;Liping Liu.;Xingquan Zhao.;Yilong Wang.;Jens Fiehler.;Yongjun Wang.;Zhongrong Miao.; .
来源: Circulation. 2025年152卷20期1397-1407页
The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0-2a) or >70% residual stenosis after thrombectomy.
2. Diastolic Blood Pressure and Cognitive Function in Adults With Achieved Systolic Blood Pressure Below 130 mm Hg: Insights From the SPRINT-MIND Trial.
作者: Ruixue Yang.;Zhou Fang.;Daman Yang.;Lei Zhang.;Qiaoxi Yang.;Qianhui Ling.;Xilan Dong.;Miaomiao Zhuang.;Tianchen Guo.;Sifei Chen.;Yufei Ji.;Jun Cai.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷11期e011902页
The potential J-shaped relationship whereby lower diastolic blood pressure (DBP) is associated with a higher risk of adverse cognitive outcomes has raised concerns regarding intensive systolic blood pressure (SBP) lowering. However, the current guidelines advocate a stricter SBP target of <130 mm Hg, with no clear consensus on a DBP target, especially with respect to brain health. The present study aimed to determine the relationship between treated DBP and cognitive function, as well as cerebral perfusion and structure, in adults who achieved an SBP <130 mm Hg.
3. Utility of 18F-Flurpiridaz PET Relative Flow Reserve in Differentiating Obstructive From Nonobstructive Coronary Artery Disease.
作者: Diana M Lopez.;Daniel M Huck.;Sanjay Divakaran.;Jenifer M Brown.;Brittany N Weber.;Mark Lemley.;Valerie Builoff.;Aakash Shanbhag.;Zhou Lan.;Christopher Buckley.;Mouaz H Al-Mallah.;Sharmila Dorbala.;Ron Blankstein.;Piotr Slomka.;Marcelo F Di Carli.
来源: Circ Cardiovasc Imaging. 2025年18卷11期e018323页
Absolute quantification of myocardial blood flow (MBF) on positron emission tomography perfusion imaging improves the identification of coronary artery disease (CAD). However, distinguishing MBF impairment due to obstructive CAD from nonobstructive CAD remains challenging. We aimed to evaluate the incremental diagnostic value of positron emission tomography derived relative flow reserve (RFR) in the diagnosis of obstructive CAD.
4. Complete Revascularization in Older Patients With Myocardial Infarction With or Without Complex Nonculprit Lesions.
作者: Alberto Sarti.;Andrea Erriquez.;Beatrice Dal Passo.;Gianni Casella.;Vincenzo Guiducci.;Raul Moreno.;Javier Escaned.;Federico Marchini.;Marta Cocco.;Filippo Maria Verardi.;Stefano Clò.;Serena Caglioni.;Jacopo Farina.;Emanuele Barbato.;Giuseppe Vadalà.;Caterina Cavazza.;Alessandro Capecchi.;Francesco Gallo.;Gianluca Campo.;Simone Biscaglia.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015902页
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease. Whether this result applies equally to patients at higher risk of ischemic events due to nonculprit lesion complexity is unclear.
5. Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation.
作者: Kenneth A Ellenbogen.;Ali Khoynezhad.;Mark La Meir.;Carlo de Asmundis.;Jayanthi N Koneru.;John Johnkoski.;Kevin Rist.;Mubashir Mumtaz.;Michael G Link.;Joris R de Groot.;Antoine H G Driessen.;Mark Y Lee.;Steven J Hoff.;David Bello.;Gansevoort Dunnington.;Susan Eisenberg.;Margot Vloka.;Benedict J Taylor.;Stephen D Jones.;Jonathan M Philpott.;Thomas M Beaver.;William M Miles.;Junaid H Khan.;Steven Kang.;Gaurang D Gandhi.;Eric J Okum.;Nitish Badhwar.;Tina Baykaner.;Anson M Lee.;Paul A Vesco.;J Michael Smith.;Sydney Gaynor.;Ken Frazier.;Randall J Lee.;Vigneshwar Kasirajan.
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e013692页
Despite advances in endocardial catheter ablation (ECA) for persistent atrial fibrillation (PersAF), undertreatment persists, especially in ECA nonresponders and in longstanding PersAF (LSPersAF), with disappointing ablation results. These patients need effective clinical treatment options.
6. Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial.
作者: Masaharu Masuda.;Yasuhiro Matsuda.;Hiroyuki Uematsu.;Hirotaka Ooka.;Satoshi Kudo.;Mizuki Ochi.;Toshiaki Mano.;Akihiro Sunaga.;Nobuaki Tanaka.;Tetsuya Watanabe.;Hitoshi Minamiguchi.;Yasuyuki Egami.;Takafumi Oka.;Tomoko Minamisaka.;Takashi Kanda.;Masato Okada.;Masato Kawasaki.;Koji Tanaka.;Nobuhiko Makino.;Hirota Kida.;Shungo Hikoso.;Tomoharu Dohi.;Koichi Inoue.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷10期e014210页
In the randomized controlled SUPPRESS-AF trial (Efficacy and Safety of Left Atrial Low-voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrillation), the efficacy of low-voltage-area (LVA) ablation was highly dependent on the degree of atrial remodeling, while the efficacy was not statistically significant in total patients. This subanalysis of the SUPPRESS-AF trial aimed to compare the efficacy of LVA ablation in patient groups classified by left atrial diameter (LAD), which is a commonly used atrial remodeling index.
7. Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation.
作者: Masahiro Natsuaki.;Hirotoshi Watanabe.;Takeshi Morimoto.;Ko Yamamoto.;Yuki Obayashi.;Ryusuke Nishikawa.;Tomoya Kimura.;Kenji Ando.;Satoru Suwa.;Tsuyoshi Isawa.;Hiroyuki Takenaka.;Tetsuya Ishikawa.;Toshihiro Tamura.;Kandoh Kawahatsu.;Fujio Hayashi.;Masaharu Akao.;Takeshi Serikawa.;Hiroyoshi Mori.;Takayuki Kawamura.;Arata Hagikura.;Naoki Shibata.;Koh Ono.;Takeshi Kimura.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015495页
There were no previous studies comparing aspirin with clopidogrel on top of oral anticoagulation (OAC) within 1 year after percutaneous coronary intervention when dual therapy with OAC and clopidogrel was recommended.
8. Patterns of Restenosis After Left Main Bifurcation Single- or Dual-Stenting: An EBC MAIN Trial Subanalysis.
作者: Annette Maznyczka.;Sandeep Arunothayaraj.;Adrian P Banning.;Thomas Schmitz.;Adrian Wlodarczak.;Marc Silvestri.;Mohaned Egred.;René Koning.;Mark S Spence.;Marie-Claude Morice.;Thierry Lefevre.;Miroslaw Ferenc.;James Cockburn.;Andrejs Erglis.;Philippe Brunel.;Francesco Burzotta.;Evgeny Kretov.;Thomas Hovasse.;Manuel Pan.;Gerald Clesham.;Alaide Chieffo.;Darren Mylotte.;Mitchell Lindsay.;Evald H Christiansen.;Frédéric Bouisset.;Beatriz Vaquerizo.;Jens Flensted Lassen.;Olivier Darremont.;Yves Louvard.;Goran Stankovic.;David Hildick-Smith.; .
来源: Circ Cardiovasc Interv. 2025年18卷11期e015546页
In the randomized EBC MAIN trial (European Bifurcation Club Left Main Coronary Stent), target lesion revascularization at 3 years poststenting of left main (LM) bifurcations was more frequent with upfront dual-stenting compared with the stepwise provisional approach. Restenosis location and its relation to stent technique are poorly characterized. The aim of this study was to investigate restenosis location after LM bifurcation stenting, and the impact of stent implantation technique.
9. Drug-Eluting Resorbable Scaffold Versus Balloon Angioplasty for Below-the-Knee Peripheral Artery Disease: 2-Year Results From the LIFE-BTK Trial.
作者: Brian G DeRubertis.;Ramon L Varcoe.;Prakash Krishnan.;Marc P Bonaca.;David J O'Connor.;Richard Pin.;David C Metzger.;Andrew Holden.;Jen-Kuang Lee.;Osamu Iida.;Ehrin J Armstrong.;Steven W C Kum.;Raghu Kolluri.;Danielle R Bajakian.;Lawrence A Garcia.;Mehdi H Shishehbor.;Shawn Yu.;Karine Ruster.;Brad J Martinsen.;Zsuzsanna Igyarto.;Sahil A Parikh.
来源: Circulation. 2025年152卷15期1076-1086页
Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK randomized controlled trial (Pivotal Investigation of Safety and Efficacy of BRS Treatment-Below the Knee), the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions. This report presents the 2-year safety and efficacy outcomes of the Esprit BTK DRS system in the LIFE-BTK randomized trial comparing DRS with PTA for treatment of infrapopliteal vessels and CLTI.
10. Accelerometer-Measured Physical Activity After Mitral Valve Surgery: An Analysis of the UK Mini Mitral Randomized Controlled Trial.
作者: Janelle M Wagnild.;Christopher Bayliss.;Rebecca H Maier.;Emmanuel Ogundimu.;Joseph Zacharias.;Enoch F Akowuah.
来源: Circulation. 2025年152卷17期1234-1245页
Wearable accelerometer devices measure free-living physical activity and sleep without relying on self-reports. Their utility to measure and compare recovery of physical function after cardiac surgery procedures has not been previously studied in the setting of a randomized controlled trial.
11. Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM Trial.
作者: Joseph Campain.;Catharine Griskowitz.;Chloe Newlands.;Brian L Claggett.;Ian J Kulac.;Shaina McGinnis.;Ilya Giverts.;Fabely Moreno.;Alexandra Minasian.;Cheshta Prasad.;Lillian Rupert.;Isabela Landsteiner.;Nick Iskenderian.;Caroline J Coats.;Matthew M Y Lee.;Martin S Maron.;Anjali T Owens.;Daniel L Jacoby.;Stephen B Heitner.;Stuart Kupfer.;Fady I Malik.;Amy Wohltman.;Rajeev Malhotra.;Gregory D Lewis.
来源: Circulation. 2025年152卷14期990-1002页
Post-exercise oxygen uptake recovery (VO2Rec) is slow in advanced heart failure. We sought to establish easily derived VO2Rec measures and evaluate their cardiospecificity and prognostic relevance in patients with dyspnea on exertion. We further sought to determine VO2Rec modifiability proportional to changes in cardiac function with disease-specific treatment of obstructive hypertrophic cardiomyopathy.
12. Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA.
作者: Chetan P Huded.;John A Spertus.;Philip G Jones.;Sean M O'Brien.;Daniel B Mark.;Sripal Bangalore.;Gregg W Stone.;David O Williams.;Harvey D White.;William E Boden.;Harmony R Reynolds.;Judith S Hochman.;David J Maron.; .
来源: Circulation. 2025年152卷12期846-858页
In ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches), an invasive strategy demonstrated better health status outcomes than a conservative strategy in patients with chronic coronary disease (CCD). Some previous studies have shown greater health status benefits with coronary artery bypass grafting (CABG) than percutaneous coronary intervention (PCI). Whether the health status benefits of invasive management in ISCHEMIA were driven primarily by participants treated with CABG is unknown.
13. Microvascular Function and Ambulatory Capacity in Peripheral Artery Disease.
作者: Alexander E Sullivan.;Adam Behroozian.;Crystal Coolbaugh.;Emily Shardelow.;Emily K Smith.;Quinn S Wells.;Daniel G Clair.;Aaron W Aday.;C Louis Garrard.;John A Curci.;Tara A Holder.;Joey V Barnett.;Matthew S Freiberg.;Rachelle L Crescenzi.;Denis J Wakeham.;Christopher M Hearon.;Manus J Donahue.;Joshua A Beckman.
来源: Circ Cardiovasc Interv. 2025年18卷10期e015582页
Patients with peripheral artery disease experience walking impairment that is incompletely explained by large-artery atherosclerotic occlusive disease and abnormal ankle-brachial index (ABI). Microvascular dysfunction is associated with adverse outcomes, including amputation, but its effect on ambulation is unknown. We tested the hypothesis that skeletal muscle microvascular function directly associates with walking distance, is a more sensitive indicator of walking distance than conduit artery blood inflow, and correlates with ambulatory improvement following peripheral artery disease interventions.
14. Atrial Mechanics in Heart Failure With Preserved Ejection Fraction: Effect of a No-Implant Interatrial Shunt.
作者: Michal Laufer-Perl.;Nir Flint.;Yaron Arbel.;Fawaz Alenezi.;Veraprapas Kittipibul.;Dmitry Yaranov.;Tamaz Shaburishvili.;Rohit Amin.;Marat Fudim.
来源: Circ Heart Fail. 2025年18卷10期e012573页
The atria play an important role in the pathophysiology of heart failure with preserved ejection fraction. Decreased left atrial strain is associated with worse clinical outcomes. The impact of no-implant interatrial shunting on atrial structure and function has not been described.
15. Impact of Cerebral Embolic Protection on Cognitive Function After Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial.
作者: James Kennedy.;Daniel J Blackman.;Matthew Dodd.;Anna Poggesi.;Laura Read.;Zahra Jamal.;Richard Evans.;Tim Clayton.;Rajesh K Kharbanda.;David Hildick-Smith.; .
来源: Circulation. 2025年152卷18期1268-1278页
In addition to the risk of stroke, patients undergoing transcatheter aortic valve implantation (TAVI) are susceptible to a decline of neurocognitive function. This may occur because of embolization of material (eg, valve or calcium) to the brain. Cerebral embolic protection (CEP) devices are engineered to capture this debris, potentially mitigating its incidence.
16. Ivabradine in Patients Undergoing Noncardiac Surgery: A Randomized Controlled Trial.
作者: Wojciech Szczeklik.;Jakub Fronczek.;Zbigniew Putowski.;Anna Włudarczyk.;Jacek Górka.;Bożena Seczyńska.;Dominika Gryszówka.;Agnieszka Widawska.;Szymon Białka.;Piotr Palaczyński.;Michał Borys.;Paweł Kutnik.;Tomasz Czarnik.;Anna Szczepańska.;Marcin Możański.;Marcin Mieszkowski.;Katarzyna Kotfis.;Janusz Trzebicki.;Łukasz Sadowski.;Joanna Sołek-Pastuszka.;Paweł Grudzień.;Wojciech Mudyna.;Agnieszka Misiewska-Kaczur.;Radosław Owczuk.;Bartosz Kudliński.;Dorota Studzińska.;Jarosław Pawlik.;Adam Makowski.;Mirosław Ziętkiewicz.;Mikołaj Przydacz.;Waldemar Goździk.;Wojciech Gola.;Przemysław Jasiewicz.;Zhiguo Zhao.;Yu Shyr.;P J Devereaux.; .
来源: Circulation. 2025年152卷16期1126-1135页
Perioperative beta blockade lowers heart rate and decreases the risk of myocardial infarction but increases the risk of hypotension, death, and stroke. Ivabradine, a selective heart rate-lowering agent, may prevent prognostically important myocardial injury after noncardiac surgery (MINS) without causing hemodynamic instability.
17. Three-Year Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients With Tricuspid or Bicuspid Aortic Stenosis.
作者: Troels Højsgaard Jørgensen.;Mikko Savontaus.;Yannick Willemen.;Øyvind Bleie.;Mariann Tang.;Oskar Angerås.;Matti Niemela.;Ingibjörg J Gudmundsdóttir.;Arif Khokhar.;Ulrik Sartipy.;Hanna Dagnegård.;Mika Laine.;Andreas Rück.;Jarkko Piuhola.;Petur Petursson.;Evald H Christiansen.;Markus Malmberg.;Peter Skov Olsen.;Rune Haaverstad.;Bernard Prendergast.;Lars Sondergaard.;Hans Gustav Hørsted Thyregod.;Ole De Backer.; .
来源: Circulation. 2025年152卷19期1326-1337页
Transcatheter aortic valve replacement (TAVR) is increasingly performed in younger, low surgical risk patients. The NOTION-2 study (The Nordic Aortic Valve Intervention) reports midterm outcomes in low-risk patients age 60 to 75 years with severe tricuspid or bicuspid aortic stenosis undergoing TAVR or surgical valve replacement.
18. Diagnostic Value of Relative Flow Reserve in Patients With Prior Coronary Artery Disease: A Post Hoc Analysis of the PACIFIC-2 Trial.
作者: Roel Hoek.;Yvemarie B O Somsen.;Ruben W de Winter.;Ruurt A Jukema.;Jos W Twisk.;Pieter G Raijmakers.;Ibrahim Danad.;Juhani Knuuti.;Paul Knaapen.;Pepijn A van Diemen.;Roel S Driessen.
来源: Circ Cardiovasc Imaging. 2025年18卷10期e018574页
The relative flow reserve (RFR) derived from quantitative myocardial perfusion imaging is the ratio of absolute myocardial perfusion in a stenotic to normally perfused area and is considered the noninvasive equivalent of fractional flow reserve (FFR). In patients with prior coronary artery disease (CAD), detecting hemodynamically significant CAD using hyperemic myocardial blood flow (hMBF) is complicated by diffuse CAD and microvascular disease. In these patients, RFR may improve the diagnostic performance of myocardial perfusion imaging. Therefore, we studied the diagnostic value of RFR over hMBF in patients with prior CAD.
19. High-Dose Versus Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.
作者: Kristoffer Grundtvig Skaarup.;Niklas Dyrby Johansen.;Daniel Modin.;Matthew M Loiacono.;Rebecca C Harris.;Marine Dufournet.;Carsten Schade Larsen.;Lykke Larsen.;Lothar Wiese.;Michael Dalager-Pedersen.;Brian L Claggett.;Katja Vu Bartholdy.;Katrine Feldballe Bernholm.;Julie Inge-Marie Helene Borchsenius.;Filip Soeskov Davidovski.;Lise Witten Davodian.;Maria Dons.;Lisa Steen Duus.;Caroline Espersen.;Frederik Holme Fussing.;Anne Marie Reimer Jensen.;Nino Emanuel Landler.;Adam Cadovius Femerling Langhoff.;Mats C H Lassen.;Anne Bjerg Nielsen.;Camilla Ikast Ottosen.;Morten Sengeløv.;Scott D Solomon.;Martin J Landray.;Gunnar H Gislason.;Lars Køber.;Pradeesh Sivapalan.;Cyril Jean-Marie Martel.;Jens Ulrik Stæhr Jensen.;Alexandre Mebazaa.;Tor Biering-Sørensen.
来源: Circ Heart Fail. 2025年18卷11期e013678页
Influenza contributes substantially to disease burden in individuals with heart failure (HF) and is an established trigger of cardiovascular and HF events. Standard-dose inactivated influenza vaccine (SD-IIV) is recommended for HF, though immune responses may be attenuated. High-dose inactivated influenza vaccine (HD-IIV) was developed to enhance immunogenicity, but its effectiveness compared with SD-IIV against hospitalization for influenza and cardiovascular disease by HF status remains uncertain.
20. Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial.
作者: Torbjørn Omland.;Siri Lagethon Heck.;Espen Holte.;Albulena Mecinaj Lilleaasen.;Mari Nordbø Gynnild.;Morten Wang Fagerland.;Victoria Vinje-Jakobsen.;Anne-Katrine Lislegaard Næs.;Egil Støre Blix.;Alf Inge Larsen.;Jürgen Geisler.;Geeta Gulati.;Torgeir Wethal.
来源: Circulation. 2025年152卷16期1136-1145页
Anthracycline- and trastuzumab-associated cardiotoxicity may lead to cardiac dysfunction and dose reduction or halt of potentially life-saving adjuvant cancer therapy. Whether angiotensin receptor/neprilysin inhibitors can prevent cancer therapy-related cardiac dysfunction and injury remains to be established.
|